QCG
UTMD icon

Quadrant Capital Group’s Utah Medical Products UTMD Stock Holding History

Quadrant Capital Group’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-128
Closed -$11K – 2788
2023
Q3 		$11K Buy
+128
New +$11.8K ﹤0.01% 1952
2022
Q2 		– Sell
-4
Closed – – 2746
2022
Q1 		$0 Buy
+4
New +$368 ﹤0.01% 2704

Other funds holding UTMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's UTMD Position: Q4 2023 in Review

Quadrant Capital Group sold out of Utah Medical Products (UTMD) in Q4 2023, closing a stake of 128 shares — an estimated $11K sold.

Quadrant Capital Group first reported a position in UTMD in Q1 2022 and held it in 2 quarters. The position peaked at $11K in Q3 2023. 89 funds tracked by Wall St. Rank hold UTMD as of Q4 2023.

  • Quadrant Capital Group reported no remaining Utah Medical Products position as of Q4 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 128 Utah Medical Products shares in Q4 2023, an estimated $11K.
  • Quadrant Capital Group first reported a position in Utah Medical Products in Q1 2022 and held it in 2 quarters.
  • Quadrant Capital Group's Utah Medical Products position peaked at $11K in Q3 2023.
  • 89 funds tracked by Wall St. Rank held Utah Medical Products as of Q4 2023.

Based on Quadrant Capital Group's 13F filing for Q4 2023, filed 8 Feb 2024.